Overexpression of an oncogenic isoform of HER2 (HER2Δ16) reduces the expression of miR-15a and miR-16 that targets BCL-2 and induces tamoxifen resistance luminal A breast cancer subtype [164]. This evidence concerns the gene ERBB2 and breast carcinoma.